# Tumescent Anesthesia Antibiotic Delivery (TAAD)

> **NCT03226626** · PHASE2,PHASE3 · UNKNOWN · sponsor: **HK Surgical, Inc.** · enrollment: 330 (estimated)

## Conditions studied

- Surgical Site Infection
- Thrombosis
- Sepsis

## Interventions

- **DRUG:** Tumescent Anesthesia and antibiotic delivery (TAAD) plus IVAD
- **DEVICE:** SubQKath

## Key facts

- **NCT ID:** NCT03226626
- **Lead sponsor:** HK Surgical, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-12-01
- **Primary completion:** 2022-01-01
- **Final completion:** 2022-07-31
- **Target enrollment:** 330 (ESTIMATED)
- **Last updated:** 2021-02-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03226626

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03226626, "Tumescent Anesthesia Antibiotic Delivery (TAAD)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03226626. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*